DexCom (DXCM) Expected to Announce Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 13th. Analysts expect DexCom to post earnings of $0.50 per share and revenue of $1.10 billion for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

DexCom Stock Performance

DXCM opened at $88.78 on Thursday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market cap of $34.68 billion, a P/E ratio of 53.16, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The business’s fifty day moving average is $81.14 and its 200-day moving average is $75.60.

Insiders Place Their Bets

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,342 shares of company stock worth $3,628,069. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DXCM. Wells Fargo & Company lifted their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Raymond James dropped their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, Canaccord Genuity Group increased their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.